Patent focus on agents for osteoporosis: September 1999 - February 2000

Bibliography

• Consensus development conference: diagnosis,prophylaxis and treatment of osteoporosis. Am. J. Med. (1993) 94:646–650.
   PubMed Web of Science ®Google Scholar
• KANIS JA, MELTON III J, CHRISTIANSEN C, JOHNSTON CC,KHALTAEV N: The diagnosis of osteoporosis. J. Bone Miner. Res. (1994) 9:1137–1141.
   PubMed Web of Science ®Google Scholar
• JARDINE PD, THOMPSON D: Anti-osteoporosis agents.Ann. Rep. Med. Chem. (1996) 31:211–220.
   Web of Science ®Google Scholar
• BARRETT-CONNOR E: The economic and human costsof osteoporotic fracture. Am. J. Med. (1995) 98 (2A):3S–8S.
   Google Scholar
• GOWEN M, EMERY JG, KUMAR S: Emerging therapiesfor osteoporosis. Emerging Drugs (2000) 5(0:1–43
   Google Scholar
• •An excellent overview of marketed osteoporosis therapies as well as those in discovery and development.
   Google Scholar
• REID IR: Pharmacological management of osteopo- in postmenopausal women. Drugs Aging (1999) 15(5) 349–363.
   PubMed Web of Science ®Google Scholar
• •A review of the efficacy of the various treatment options available for osteoporosis.
   Google Scholar
• BUSH TL, WELLS HB, JAMES MK et al:Effects of hormonetherapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEPO trial. jAm. Med. Assoc. (1996) 276 (17) :1389–1396.
   PubMed Web of Science ®Google Scholar
• BERAL V, BULL D, DOLL R, KEY T, PETO R, REEVES G:Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiol-ogical studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet (1997) 350:1047–1059.
   PubMed Web of Science ®Google Scholar
• LOVE RR, MAZESS RB, BARDEN HS et al: Effects oftamoxifen on bone mineral density in postmeno-pausal women with breast cancer. N Engl. J. Med. (1992) 326:852–856.
   PubMed Web of Science ®Google Scholar
• LUFKIN EG, WHITAKER MD, NICKELSEN T et al.:Treatment of established postmenopausal osteopo-rosis with raloxifene: a randomized trial../. Bone Miner. Res. (1998) 13: 1747-1754.
   Google Scholar
• ETTINGER B, BLACK DM, MITLAK BH et al.: Reduction ofvertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. Results from a 3-year randomized clinical trial. J. Am. Med. Assoc. (1999) 282(7):637–645.
   Google Scholar
• KUIPER G, ENMARK E, PELTO-HUIKKO M, NILSSON S,GUSTAFSSON J: Cloning of a novel estrogen receptor expressed in rat prostate and ovary. Proc. Natl. Acad. Sci. USA (1996) 93:5925–5930.
   PubMed Web of Science ®Google Scholar
• MOSSELMAN S, POLMAN J, DIJKEMA R: ER: identifica-tion and characterization of a novel human estrogen receptor. FEBS Lett. (1996) 392:49–53.
   PubMed Web of Science ®Google Scholar
• MUNDY G, GARRETT R, HARRIS S et al: Stimulation of bone formation in vitro and in rodents by statins. Science (1999) 286:1946–1949.
   PubMed Web of Science ®Google Scholar
• ••Demonstrates that the orally bioavailable statins are capableof stimulating new bone formation.
   Google Scholar
• MARGOLIS RN, CANALIS E, PARTRIDGE NC: Invited review of a workshop: anabolic hormones in bone: basic research and therapeutic potential. J. Clin. Endocrinol. Metab. (1996) 81(3):872–877.
   PubMed Web of Science ®Google Scholar
• SMITH WW, ABDEL-MEGUID SS: Cathepsin K as a target for the treatment of osteoporosis. Exp. Opin. Ther. Patents (1999) 9(6):683–694.
   Web of Science ®Google Scholar
• SAFTIG P, HUNZIKER E, WEHMEYER 0 et al.: Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice. Proc. Natl. Acad. Sci. USA (1998) 95:13453–13458.
   Google Scholar
• GOWEN M, LAZNER F, DODDS R et al: Cathepsin K knockout mice develop osteopetrosis due to a deficit in matrix degradation but not demineralization. J. Bone Min. Res. (1999) 14:1654–1663.
   PubMed Web of Science ®Google Scholar
• VOTTA BJ, LEVY MA, BADGER A et al.: Peptide aldehyde inhibitors of cathepsin K inhibit bone resorption both in vitro and in vivo. J. Bone Min. Res. (1997) 12 (9) :1396–1406.
   PubMed Web of Science ®Google Scholar
• •A cathepsin K inhibitor significantly reduces bone loss in an adjuvant-arthritic rat model.
   Google Scholar
• XIA L, KILB J, WEX H et al: Localization of rat cathepsin K in osteoclasts and resorption pits: inhibition of bone resorption and cathepsin K-activity by peptidyl vinyl sulfones. Biol. Chem. (1999) 380:679–687.
   PubMed Web of Science ®Google Scholar
• DRAKE FH, DODDS RA, JAMES IE et al.: Cathepsin K, but not cathepsins B, L, or S, is abundantly expressed in human osteoclasts. J. Biol. Chem. (1996) 271 (20 :12511–12516.
   PubMedGoogle Scholar
• YASUMA T, OI S, CHOH N et al: Synthesis of peptidealdehyde derivatives as selective inhibitors of human cathepsin L and their inhibitory effect on bone resorp-tion. J. Med. Chem. (1998) 41:4301–4308.
   PubMed Web of Science ®Google Scholar
• •A cathepsin L inhibitor, dosed orally, prevented bone loss in OVX mice.
   Google Scholar
• ENGLEMAN VW, KELLOGG MS, ROGERS TE: Cell adhesion integrins as pharmaceutical targets. Ann. Rep. Med. Chem. (1996) 31:191–200.
   Web of Science ®Google Scholar
• ROBEY PG: RGD-containing proteins and bone. Ann. Rep. Med. Chem. (1993) 28:227–236.
   Web of Science ®Google Scholar
• LARK MW, STROUP GB, HWANG SM et al.: Design and characterization of orally active Arg-Gly-Asp peptidomimetic vitronectin receptor antagonist SB 265123 for prevention of bone loss in osteoporosis. J. Pharmacol. Exp. Ther. (1999) 291:612–617.
   PubMed Web of Science ®Google Scholar
• •An orally-active RGD mimetic inhibits bone resorption in vivo in the OVX rat model.
   Google Scholar
• ENGLEMAN VW, NICKOLS GA, ROSS FP et al.: A peptidomimetic antagonist of the a,,,p3 integrin inhibits bone resorption in vitro and prevents osteoporosis in vivo. J. Clin. Invest. (1997) 99(9)2284–2292.
   Google Scholar
• SORIANO P, MONTGOMERY C, GESKE R, BRADLEY A:Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell (1991) 64:693–702.
   PubMed Web of Science ®Google Scholar
• MISSBACH M, JESCHKE M, FEYEN J et al.: A novelinhibitor of the tyrosine kinase src suppresses phosphorylation of its major cellular substrates and reduces bone resorption in vitro and in rodent models in vivo. Bone (1999) 24(5):437–449.
   PubMed Web of Science ®Google Scholar
• •An Src kinase inhibitor, dosed orally, prevents bone loss in OVX rats.
   Google Scholar
• BROWN EM, GAMBA G, RICCARDI D et al.: Cloning andcharacterization of an extracellular Ca2±-sensing receptor from bovine parathyroid. Nature (1993) 366:575–580.
   PubMed Web of Science ®Google Scholar
• BROWN EM, VASSILEV PM, HEBERT SC: Calcium ions asextracellular messengers. Cell (1995) 83:679–682.
   PubMed Web of Science ®Google Scholar
• LINDSAY R, NIEVES J, FORMICA C et al.: Randomizedcontrolled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteopo-rosis. Lancet (1997) 350:550–555.
   PubMed Web of Science ®Google Scholar
• GOWEN M, STROUP BG, BRADBEER JN et al. An antago- of the parathyroid cell Ca2+ receptor stimulates PTH secretion and bone turnover in osteopenic ovariectomized rats. Bone (1998) 23(55):5163.
   Google Scholar
• PILBEAM CC, HARRISON JR, RAISZ LG: Prostaglandinsand bone metabolism. In: Principles of Bone Biology. Bilezikian JP, Raisz LG, Rodan GA (Eds.), Academic Press (1996):715–728.
   Google Scholar
• MA YF, LI XJ, JEE WSS et al.: Effects of prostaglandin E2and E2a on the skeleton of osteopenic ovariectomized rats. Bone (1995) 17(6):549–554.
   PubMed Web of Science ®Google Scholar
• SCHMITT JM, HWANG K, WINN SR, HOLLINGER JO: Bonemorphogenetic proteins: an update on basic biology and clinical relevance. J. Orthop. Res. (1999) 17:269–278.
   PubMed Web of Science ®Google Scholar
• SAKOU T: Bone morphogenetic proteins: from basicstudies to clinical approaches. Bone (1998) 22 (6):591–603.
   PubMed Web of Science ®Google Scholar
• ODA T, NOTOYA K, GOTOH M et al.: Synthesis of novel2-benzothiopyran and 3-benzothiepin derivatives and their stimulatory effect on bone formation. J. Med. Chem. (1999) 42:751–760.
   PubMed Web of Science ®Google Scholar
• NOTOYA K, NAGAI H, ODA T et al.: Enhancement of osteogenesis in vitro and in vivo by a novel osteoblast differentiation promoting compound, TAK-778. J. Pharmacol. Exp. Ther. (1999) 290:1054–1064.
   PubMed Web of Science ®Google Scholar
• ••A small molecule enhances new bone formation in vivo inbony defect and osteotomy animal models.
   Google Scholar